Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease

Background/Aims Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, and encompasses both ulcerative colitis (UC) and Crohn’s disease (CD). Refractory disease is common, a combination of advanced drug therapies may be required to obtain maximal eff...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Robert Gilmore, Amrutha Murali, Amirah Etchegaray, Ei Swe, Yoon-Kyo An, Jakob Begun
Format: Artigo
Jezik:Inglês
Izdano: Korean Association for the Study of Intestinal Diseases 2025-10-01
Serija:Intestinal Research
Teme:
upadacitinib
vedolizumab
combination therapy
ulcerative colitis
crohn disease
Online dostop:http://irjournal.org/upload/pdf/ir-2024-00174.pdf
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki